Dupixent and Narrowband UVB for Atopic Dermatitis
Recruiting · NCT05285839 · Interventional (participants receive a specific treatment) · Lead sponsor: Psoriasis Treatment Center of Central New Jersey
View the official record on ClinicalTrials.gov →Interventions studied
Dupixent
What this trial is about
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 4
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Male or female adult ≥ 18 years of age;
- Diagnosis of moderate to severe atopic dermatitis as defined at baseline by:
- EASI score of 16 or greater,
- IGA score of 3 or greater
- BSA of 10% or greater,
Exclusion criteria
- Subjects with previous exposure to dupilumab.
- Known or suspected hypersensitivity to dupilumab or any of its excipients.
- History of photosensitivity.
Where it is running
1 location listed across 1 US state.
- Eczema Treatment Center of New Jersey - East Windsor, New Jersey, United States